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Background: Hypoglycaemia has been associated with increased cardiovascular (CV) risk and mortality in a number
of recent multicentre trials, but the mechanistic links driving this association remain ill defined. This review aims to
summarize the available data on how hypoglycaemia may affect CV risk in patients with diabetes.
Methods: This was a systematic review of available mechanistic and clinical studies on the relationship between
hypoglycaemia and cardiovascular risk. Study outcomes were compiled from relevant articles, and factors
contributing to hypoglycaemia-mediated CVD and its complications are discussed.
Results: Six recent comprehensive clinical trials have reinforced the critical importance of understanding the link
between hypoglycaemia and the CV system. In addition, 88 studies have indicated that hypoglycaemia
mechanistically contributes to CV risk by increasing thrombotic tendency, causing abnormal cardiac repolarization,
inducing inflammation, and contributing to the development of atherosclerosis. These hypoglycaemia-associated
risk factors are conducive to events such as unstable angina, non-fatal and fatal myocardial infarction, sudden
death, and stroke in patients with diabetes.
Conclusions: Emerging data suggest that there is an impact of hypoglycaemia on CV function and mechanistic link
is multifactorial. Further research will be needed to ascertain the full impact of hypoglycaemia on the CV system
and its complications.
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In patients with type 1 (T1D) and type 2 diabetes (T2D),
cardiovascular (CV) disease is the most common cause
of death (45% and 52%, respectively) [1-3]. Since diabetes
is a disease of glucose intolerance, most studies have fo-
cused on elucidating the role of hyperglycaemia on CV
complications. However, recent reports have also begun
to highlight the potential importance of hypoglycaemia-
mediated adverse effects [4-6].
Episodes of hypoglycaemia are frequent in diabetic pa-
tients undergoing intensive glucose lowering therapy. In
fact, hypoglycaemia constitutes the principal reason that
blood glucose targets are not achieved in many patients
[7]. Interestingly, recent studies that specifically exam-
ined the benefits of intensive glucose lowering therapy
such as the Action to Control Cardiovascular Risk in* Correspondence: hanefeld@gwtonline-zks.de
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reproduction in any medium, provided the orDiabetes (ACCORD) [8] trial, the Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE) study [9] and
the Veteran’s Affairs Diabetes Trial (VADT) [10], did not
observe a reduction in CV risk. Instead, these trials dem-
onstrated significantly increased rates of hypoglycaemia
in the intensive treatment arms, which was implicated
in the lack of a benefit and possibly even excess mortal-
ity in the ACCORD trial [8,11].
Because hypoglycaemia is often asymptomatic, it is
difficult to establish a direct association with mortality.
Nevertheless, efforts have been made to identify pos-
sible mechanistic links between hypoglycaemia and CV
complications during diabetes treatment. So far, it has
been suggested that acute or recurrent hypoglycaemic
episodes could induce thrombosis and inflammation [12],
abnormal cardiac repolarization, arrhythmia and atrial fib-
rillation [13], endothelial injury [14], myocardial ischemia
and cerebral damage [15], and preclinical atherosclerosisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Criteria of high, moderate and low study quality
Study quality Criteria
High: small risk of bias Prospective study design and
the following:
- Adequately described patients
constituting a representative and
clinically relevant sample
- Sample size ≥ 5000
Moderate: moderate risk of bias Prospective study design
Low: high risk of selection and/or
verification bias
Retrospective study design
Selected or enriched samples
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cose levels and the unexpected sudden death of patients
with type 1 diabetes without CVD, also known as “dead in
bed” syndrome [17].
The effects of hypoglycaemia are poorly established
and sometimes overlooked, but can have potentially life-
threatening consequences [18]. Because of this, we aimed
to review the available data regarding the impact of
hypoglycaemia on cardiac complications and mortality
in patients with diabetes.
Methods
Search strategy
An electronic literature search of PubMed up to November
2012 was performed using a combination of subject
headings and free text incorporating “hypoglycaemia”,
“cardiac OR heart”, “QTc”, “arrhythmia”, “endothelium”,
“thrombosis”, “inflammation”, “atherosclerosis”, “heart
rate”, “heart failure”, “myocardial ischemia”, “myocardial
infarction”, “coronary heart disease”, and “angina”. The
search was then extended by manually screening the
reference lists of included papers.
Study selection
Identified sources where evaluated according to the
PRISMA statement for reporting systematic reviews and
meta-analyses of studies [19]. Papers were first subdivided
based on whether they were clinical trials involving
glycaemic control or studies related to the underlying
pathophysiologic mechanisms linking hypoglycaemia
with CV risk. Included clinical studies fulfilled all of the fol-
lowing criteria: (1) published as a primary research paper
in a peer-reviewed journal; (2) included cohorts of patients
with T1D or T2D under intensive glucose-lowering ther-
apy; and (3) reporting the proportion of patients present-
ing with CV complications. Studies of only highly selected
groups (e.g. undergoing cardiac surgery or case reports),
and conference proceedings were excluded. Included mech-
anistic studies fulfilled the following criteria: (1) published
as a primary research paper in a peer-reviewed journal,
and (2) investigated direct mechanistic links between
hypoglycaemia-induced physiologic effects and CV risk.
Only papers in English were selected. One reviewer per-
formed the search and screened the titles and abstracts
to exclude irrelevant papers. Full-text articles were then
reviewed by at least two reviewers to assess eligibility,
and consensus was sought to resolve any disagreement
between researchers.
Quality assessment
We applied the Critical Appraisal Skills Programme guide-
lines for quality assessment and excluded studies with major
limitations in methods or reporting [20]. In addition, thequality of each included study was rated high, moderate or
low according to pre-specified markers of quality (Table 1).
Data collection and analysis
Characteristics of included studies were extracted independ-
ently by two researchers using a standardised form. These
included study design, population, treatments, and CV out-
come. A qualitative analysis of the texts was performed.
Results
Definition and frequency of hypoglycaemia
Definition
There has been some debate over which biochemical
definition of hypoglycaemia should be used in clinical
settings [21]; however, the most well-known classifica-
tion put forth by the American Diabetes Association
(ADA) Workgroup on Hypoglycaemia [22] included cri-
teria for five categories of hypoglycaemia: severe hypogly-
caemia (requiring aid of another person to administer
treatment), documented symptomatic hypoglycaemia
(common hypoglycaemic symptoms and measured plasma
glucose of ≤ 70 mg/dL [3.9 mmol/L]), asymptomatic
hypoglycaemia (not accompanied by symptoms but glu-
cose measurement of ≤ 70 mg/dL [3.9 mmol/L]), probable
symptomatic hypoglycaemia (self-reported symptomatic
episode not verified by glucose determination), and rela-
tive hypoglycaemia (symptoms associated with plasma
glucose > 70 mg/dL [3.9 mmol/L]). Importantly, hypogly-
caemia often occurs during sleep, and these episodes
of “nocturnal hypoglycaemia” can range from asymptom-
atic to severe. From Continous Glucose Monitoring
System (CGMS) studies it is known that the majority of
critical low (< 3.1 mmol/l) glucose nocturnal episodes
remain unrecognized [23].
Normally, when blood glucose levels fall below the
threshold for supporting normal cognitive function, the
body initiates glucose counter-regulatory measures, which
include release of glucagon and epinephrine. However, an
important response driven by recurrent hypoglycaemia
in T1D and advanced T2D involves the impairment of
physiological mechanisms that normally defend against
Hanefeld et al. Cardiovascular Diabetology 2013, 12:135 Page 3 of 11
http://www.cardiab.com/content/12/1/135declining plasma glucose levels. This is especially true
for patients with T1D, who lose normal glucagon re-
sponse to hypoglycaemia within five years of diagnosis
and have attenuated epinephrine release [24]. This leads
to the development of “hypoglycaemia unawareness”,
which involves the loss of the hypoglycaemia-related
symptoms that normally alert diabetic patients to take
corrective action [25]. As a result, recurrent and un-
noticed cycles of potentially dangerous hypoglycaemia
can ensue, particularly in the case of insulin-requiring
diabetes. Individuals with impaired hypoglycaemia aware-
ness have a six-fold increased risk for experiencing severe
hypoglycaemia [26], and attenuated physiological responses
to critical low glucose levels might be fatal [27].Frequency
Hypoglycaemia is a frequent finding resulting from in-
adaequate insulin dosing in T1D. In fact, patients with
T1D experience thousands of mild (glucose < 70 mg/dL)
hypoglycaemic episodes over a lifetime of diabetes, suf-
fering on average two episodes of symptomatic hypo-
glycaemia per week, and at least one severe episode per
year [28]. A 2007 study reported the incidence of severe
hypoglycaemia to be 110 episodes per 100 patient-years
in patients with T1D treated with insulin for <5 years
and 320 episodes per 100 patient-years in those treated
for >15 years with insulin [7]. Also, it has been sug-
gested that 6-10% of deaths in patients with T1D could
result from hypoglycaemia [29,30].Identification
Total records
identified: 744
No. of clinical trials involving 















Figure 1 Flow diagram of the study identification process.In the case of T2D, hypoglycaemia may be less frequent,
and usually results from the use of drugs that cause in-
creased endogenous insulin levels (e.g. sulfonylureas) or
treatment with exogenous insulin [31-34]. If T2D patients
were treated with insulin, the overall rate of hypoglycaemia
was reported to be low [11] and about one third that of pa-
tients with T1D [35]; however, when considering advanced
stages of T2D, the frequency approaches that of T1D [7]. It
is particularly difficult in a frail elderly population which
not only have a high risk for developing hypoglycaemia but
also because of their hypoglycaemia associated autonomic
failure [36].
High quality clinical studies on glycaemic control and CV
outcome in diabetes
The most common cause of death in diabetes is CV dis-
ease (CVD) [1,2], and there exists a bulk of evidence that
hypoglycaemia is a serious CV risk factor [4,5]. Six high
quality studies have examined CV outcome while compar-
ing intensive glucose-lowering treatment with conventional
therapy (Figure 1 & Table 2).
The Diabetes Control and Complications Trial (DCCT),
analysing 1,441 T1D patients [39], observed increased hypo-
glycaemia rates with intensive therapy (insulin pump or
three or more insulin injections per day). The trial initially
found no effects on CVD, but in a follow-up study, the
Epidemiology of Diabetes Interventions and Complica-
tions (EDIC) trial, a delayed benefit was described [40].
Similar to these data the United Kingdom Prospective
Diabetes Study (UKPDS), which enrolled 5,102 newlyes analyzing mechanistic links 
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Table 2 Characteristics of high quality clinical trials identified (adapted from [37,38])
Study Population Design Treatments Outcome
DCCT/EDIC
[39,40]
1,441 T1D adolescents and adults
(13–39 years old) with diabetes
duration of 1–15 years






pump) vs. standard therapy
↓CVD by 54%, but only evident after
long-term (>12-yr.) follow-up
UKPDS [41,42] 5,102 newly diagnosed T2D adults Randomized control trial of






No significant differences in CV
outcomes after trial, but 10-yr.




10,251 T2D patients, 40–79 years
of age with CV or 55–79 years of
age with atherosclerosis or ≥ two
risk factors
3.5 yr. study; Randomized





Study stopped early because of
increased overall and CV mortality;
primary CVD endpoint ↓10% (P=0.16);
overall mortality ↑22% (P=0.04);
CV mortality ↑35% (P=0.02)
ADVANCE [9] 11,140 patients with T2D in 20
countries, ≥55 years of age and
≥30 years of age at diagnosis
5 yr. study; tested if glucose
lowering affected CV risk in





No difference in CV end point by
treatment group; primary CVD
endpoint ↓6% (P=0.37); overall




1,791 patients with T2D on insulin
or maximal-dose oral agents
5.6 yr. study; determined
effect of intensive glycaemic
control on CV risk
Intensive treatment (<6.0%)
vs. standard treatment
No difference in CV end point by
treatment group; primary CVD
endpoint ↓13% (P=0.12); overall
mortality ↑6.5% (P=NS); CV mortality
↑25% (P=NS)
ORIGIN [47] 12,537 patients with IFG, IGT or
T2D on insulin glargine or standard
of care
6.2 yr study; determined
effect of early insulin
treatment on CV events
Insulin glargine vs. standard
of care
No differences in the rate of CV events
(P=0.63/0.27)
ACCORD Action to Control Cardiovascular Risk in Diabetes, ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled
Evaluation, CVD, cardiovascular disease, DCCT Diabetes Control and Complications Trial, EDIC Epidemiology of Diabetes Interventions and Complications, HbA1c
glycosylated haemoglobin, IFG impaired fasting glucose, IGT impaired glucose tolerance, ORIGIN Outcome Reduction with Initial Glargine Intervention, T1D type 1
diabetes, T2D type 2 diabetes, UKPDS United Kingdom Prospective Diabetes Study.
Hanefeld et al. Cardiovascular Diabetology 2013, 12:135 Page 4 of 11
http://www.cardiab.com/content/12/1/135diagnosed T2D patients [41,42], found no significant
reduction in CV complications and higher rates of severe
hypoglycaemia with intensive therapy. However, a 10-year
follow-up identified modest post-trial risk reductions [42],
again suggesting a delayed benefit. More recently, the
ACCORD trial studied 10,252 T2D patients with existing
CVD and/or CV risk factors [8], but the trial was inter-
rupted due to excess mortality with intensive treatment.
While the rate of hypoglycaemia again grew with intensive
therapy, post-analysis of the study concluded that it did
not account for the rise in mortality rate [43,44]; however,
it is difficult to exclude the contribution of hypoglycaemia
[37]. In contrast, the ADVANCE study, which analysed
11,140 T2D patients [9], did not observe increased mortal-
ity. However, intensive therapy again led to hypoglycaemia,
which was linked to vascular events and CV-related death
[6]. Also, when 1,791 military veterans with poorly con-
trolled T2D were studied in the VADT [45], intensive
therapy-related hypoglycaemia with no CV benefit was
again observed.
ORIGIN (Outcome Reduction With Initial Glargine
Intervention) [47] was somewhat different from the afore-
mentioned trials in that it included patients with type 2
diabetes but also patients with pre-diabetes but high car-
diovascular risk. At an almost identical HbA1c (ORIGIN6.2%, ACCORD 6.4%) severe hypoglycemia was infrequent
in the glargine arm of ORIGIN but much more frequent
in the intensified treatment arms of ACCORD (3.1%) and
VADT (3.8%). This has to be interpreted however on
the background of a longer diabetes duration (10 years
in ACCORD and 11.5 years in VADT vs. 5 yrs in ORIGIN)
and high baseline HbA1c values (8.1% in ACCORD, 9.4%
in VADT vs. 6.4% in ORIGIN).
Therefore, while these studies collectively showed no
CV-related benefit, it was evident that intensive therapy
increased hypoglycaemia, suggesting that it might repre-
sent a barrier for treatment. Thus, investigations have
begun to unravel the complex mechanistic relationship
between hypoglycaemia and the CV system.Mechanistic studies linking hypoglycaemia and CV risk
in diabetes
Our search resulted in 572 studies identifying specific
hypoglycaemia-induced pathophysiological changes that
might drive CV risk in diabetes, of which 484 were excluded
based on relevance and quality (Figure 1 & Table 3). Based
on these findings, we will discuss the key hypoglycaemia-
mediated risk factors that are currently thought to pro-
mote CVD.
Table 3 Hypoglycaemia-mediated effects contributing to
cardiovascular dysfunction
Risk factor Hypoglycaemic-associated effect
contributing to risk factor
Reference(s)
Thrombotic tendency ↑ platelet-monocyte aggregation [14]
↑ soluble P-selectin levels [14,48]
↑ plasminogen activator inhibitor-1 [48]
↓ partial thromboplastin time [49]
↑ fibrinogen and factor VIII [49]
Abnormal cardiac
repolarization
↑ catecholamines (hypokalaemia) [14,50-52]
Inflammation ↑ QT interval and QT dispersal [13,53-56]
↑ CD40 expression on monocytes [14]
↑ soluble CD40L in serum [14]
↑ IL-6, IL-8, TNF-α, and IL-1β [57-60]
↑ ICAM, VCAM, E-selectin, and VEGF [48,57]
Atherosclerosis ↑ inflammation see above
↑ endothelial dysfunction [14,57,60]
↑ oxidative stress [57]
↑ Aldosterone [61]
↑ ICAM, VCAM, and E-selectin [48]
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One result of hypoglycaemia is activation of the sympatho-
adrenal system and release of glucagon and catecholamines
(such as epinephrine), which stimulate hepatic glucose
production and haemodynamic changes in an attempt
to supply glucose to the brain [13,14,50,51]. Although
these changes constitute a physiological protective mech-
anism, they can be detrimental for frail diabetic patients
that have developed endothelial dysfunction (perhaps
resulting from their disease) or already suffering from
coronary artery disease with ischemia and unstable plaques.
In particular, direct epinephrine-mediated CV effects, in-
cluding increased heart rate and systolic blood pressure,
fall in central blood pressure and peripheral resistance,
which may be fatal in the case of pre-existing advanced
vascular lesions, as well as increased stroke volume and
cardiac output can be hazardous for diabetic patients [62].
Epinephrine can also induce hypokalaemia, leading to
consequences on cardiac function such as arrhythmia
[52,63]. Collectively, these transient stresses can have
dangerous consequences during diabetes, leading to con-
vulsions, loss of consciousness, and even coma.
Thrombocytes
Hypoglycaemia is known to result in enhanced platelet
aggregation [64], and lead to decreased partial thrombo-
plastin time, diminished platelet counts, and increased
fibrinogen and factor VIII in T1D patients [49]. More
recently, it was confirmed that hypoglycaemia promotedplatelet activation, which was measured via increased
platelet-monocyte aggregation and soluble P-selectin levels
[14], as well as increased plasminogen activator inhibitor-1
(PAI-1) levels in T1D [48]. Hypoglycaemia-induced alter-
ations in these coagulation cascade-related factors could
have severe effects on the CV system, contributing to the
occurrence of major vascular events such as myocardial
infarction or stroke.QTc interval / arrhythmia
The hypoglycaemic state is known to affect the electrocar-
diogram (ECG), resulting in lengthening of the corrected
QT interval (QTc) and increased QT dispersion (QTd)
during cardiac repolarization [13,53] (Figure 2). These have
been identified to have prognostic value in a recent ana-
lysis of the PROspective PioglitAzone Clinical Trial In
MacroVascular Events (PROactive) trial, where electro-
cardiographic signs such as heart rate, QTc-interval and
bundle branch blocks were predictive for adverse outcome
[65]. This is sufficient to cause life-threatening cardiac
arrhythmias, such as ventricular tachycardia [66] and
atrial fibrillation [67] or sudden death with ventricular
fibrillation as the principal reason [25]. This variation
in cardiac function is thought to occur in response to
hypoglycaemia-induced sympatho-adrenal changes, which
ultimately lead to decreased circulating potassium and
direct effects of catecholamines on myocardium ion
channels [13]. In support of this, one study found that
the neurogenic symptoms of hypoglycaemia are largely
the result of sympathetic neural activation, while the
hemodynamic responses stem mainly from the adrenomed-
ullary system [68]. However, hypoglycaemia can also alter
cardiac autonomic regulation by reducing vagal outflow
[69]. Altogether, these pathways act synergistically to
promote arrhythmic potential. It has been shown that
arrhythmias related to hypoglycaemia and excessive gly-
cemic variability dramatically increases mortality in pts.
with heart failure [7].
Although these hypoglycaemia-mediated changes in
heart function are considered to contribute to risk for
CV-related death in diabetes, no causal link between
acute hypoglycaemic episodes and mortality has truly
been documented. In fact, case reports have merely sug-
gested that there may be a temporal relationship between
hypoglycaemia, adverse cardiac outcomes, and sudden
death. For instance, angina following an acute episode
of hypoglycaemia was reported, and hypoglycaemia second-
ary to a massive insulin overdose produced ECG and en-
zyme changes associated with acute coronary syndromes
[70]. Another study of 6 subjects with T2D found that
hypoglycaemia was accompanied by altered ECG configu-
rations and changes in the plasma concentrations of cate-
cholamines and potassium [71].
Figure 2 Effect of experimental hypoglycaemia on QT interval. Typical QT measurement with a screen cursor placement from a subject
during euglycaemia (a), showing a clearly defined T wave, and hypoglycaemia (b), showing prolonged repolarization and a prominent U wave.
Horizontal: 799 ms epoch, vertical: 1.33 mV full scale (adapted from Marques et al. [55]).
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hypoglycaemia and death by arrhythmia, probably the best
evidence for this relationship comes from continuous glucose
monitoring (CGM) studies. In fact, hypoglycaemia-associated
ECG abnormalities were documented in a study using CGM
and cardiac Holter monitoring in 19 patients with coronary
artery disease and T2D [72]. Out of 54 recorded
hypoglycaemic episodes, 26 were symptomatic. Of these, 10
were associated with chest pain, 4 of which were accompan-
ied by ECG abnormalities. Importantly, the difference be-
tween the frequency of ischemia during hypoglycaemia and
normoglycaemia was statistically significant (p<0.001).
Interestingly, severe hypoglycaemic attacks in T1D pa-
tients have also been shown to be independently associated
with QTc prolongation in T1D patients [73], and increased
QTd, but not prolonged QTc interval, was shown to be as-
sociated with CV mortality in T2D [74]. However, it must
be noted that it was also suggested that hypoglycaemia has
only modest effects on QTc, and that misleading results
have been obtained during repolarization analysis [75].
Nevertheless, the existing data collectively suggest that
ECG abnormalities occurring during hypoglycaemia might
be life threatening for patients with diabetes.
Nocturnal hypoglycaemia / dead in bed syndrome
Nocturnal hypoglycaemia can also induce QTc prolonga-
tion and cardiac rate/rhythm disturbances in T1D [54-56].
This is especially relevant considering the fact that severe
hypoglycaemia is known to occur more often during sleep
for T1D patients [76] (Figure 3). In fact, there is evidence
that early nocturnal sleep shifts the activation ofneuroendocrine-mediated, counter-regulatory measures in
the direction of lower glucose thresholds, while late noc-
turnal sleep reduces the induction of counter-regulatory
mechanisms [27]. As a result of these attenuated physio-
logical reactions, critical low plasma glucose levels can
remain undetected within the hypoglycaemic range for
longer periods of time. Thus, nocturnal hypoglycaemia
may be more likely to trigger cardiac arrhythmias, pla-
cing patients at risk. For this reason, researchers have
begun to more deeply investigate the relationship be-
tween nocturnal hypoglycaemia and the CV risk.
Interestingly, one study of nocturnal hypoglycaemia
monitored 22 subjects with T1D using CGM and hourly
assessment of plasma potassium, catecholamines, and
ECG outputs [56]. Hypoglycaemia occurred on 7 of the
22 (32%) nights of the study, and the QTc interval was
significantly prolonged during these hypoglycaemic nights
(P =0.034). Moreover, adrenaline secretion increased sig-
nificantly during hypoglycaemia, while serum potassium
and noradrenaline did not. Overall, the counter-regulatory
response was attenuated, consistent with the hypothesis
that cardiac repolarization and hypoglycaemia-induced
sympathoadrenal activation are related. These findings
were partly confirmed in a subsequent investigation of 44
young individuals with T1D [77]. Prolonged QTc occurred
on 20 out of 74 (27%) nights and was more prevalent on
nights with hypoglycaemia. Additionally, another study
involving 25 T1D patients, who underwent two separate
24-hour periods of ECG monitoring and CGM in an
ambulatory setting, found a similar rate of nocturnal
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Figure 3 “Dead in bed” syndrome (adapted from Tanenberg et al. [17]). Glucose levels captured by the retrospective continuous subcutaneous
glucose monitoring system (CGMS) for the evening before and the morning of the patient’s death. The calibrations measured and entered by the
patient are represented by the 4 circles. The timing of the patient’s meals, exercise, and correction insulin boluses are represented by the bars along the
bottom of the graph. The precipitous decrease in glucose level after the correction doses can be observed to start just after midnight, and possible
counterregulatory efforts are noted once the glucose level declined to below 30 mg/dL shortly after 2 am.
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diac rate/rhythm disturbances (other than sinus tachycar-
dia) were seen 62% of the episodes.
Taken together, this suggests that during sleep diabetics
might have increased risk for hypoglycaemia-associated CV
issues and death. Data are however mostly related to pa-
tients with T1D and data are missing for those with T2D. In
fact, a 1991 study in the U.K., postulated that hypoglycaemia
was the cause of 22 unexpected deaths in young T1D pa-
tients, who died during the night and were discovered lying
in an undisturbed bed [78]. Moreover, these cases, which
were coined “dead in bed syndrome”, seemed to be on the
rise at the time of their discovery [79]. These deaths were
first connected with the use of human insulin; however, they
are now mostly attributed to the trend toward intensive
therapy with multiple daily doses of fast acting insulin. In
fact, as described, the Diabetes Control and Complications
Trial (DCCT) found that intensive therapy was associated
with increased rates of severe hypoglycaemia in T1D [80].
So far, the frequency of dead in bed syndrome has been sug-
gested to be 5–6% of all deaths in diabetic patients <40 years
old [79,81]. Thus, hypoglycaemia-mediated changes in car-
diac repolarization and subsequent arrhythmia can have
grave consequences for diabetics and might contribute to
unexpected diabetes-related deaths.Inflammation and atherosclerosis
It has become increasingly clear that one consequence of
hypoglycaemia is induction of inflammation. During acute
insulin-induced hypoglycaemia, patients with T1D not only
demonstrated an increase in both CD40 expression on
monocytes and plasma sCD40L concentrations [14], but
also upregulation of ICAM, VCAM, E-selectin and VEGF,
indicating an inflammatory response [48,57]. Additionally,
hypoglycaemia led to increased serum levels of the pro-
inflammatory cytokine IL-6 [48,57,58], and this was con-
firmed along with additional inflammatory cytokines, includ-
ing TNFα, IL-1β, and IL-8 [59]. Moreover, there is evidence
that TNFα and/or inflammation are driving forces for CV
complications during hypoglycaemia. In fact, increased
circulating NH2-terminal pro-brain natriuretic peptide
(NTproBNP), which is a marker of vascular dysfunction,
was associated with TNFα upregulation in T1D [60]. Also,
upregulation of inflammatory cytokines and markers were
independently associated with vascular disease in T1D pa-
tients [82].
In addition, increases in both serum tissue plasminogen
activator (tPA) and aldosterone, a hormone involved in vas-
cular injury, have been reported under hypoglycaemic con-
ditions, suggesting that hypoglycaemia drives endothelial
dysfunction [14,61]. Moreover, it was suggested that brief
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sion favouring CV risk [83].
Importantly, repeated cycles of hypoglycaemia lead to
more severe/prolonged inflammation, oxidative stress, and
ultimate endothelial dysfunction [57], which might explain
why cyclic hypoglycaemia is an aggravating factor for the de-
velopment of preclinical atherosclerosis during T1D [16]. In
addition, the previously discussed increases in adhesion
markers (ICAM, VCAM, E-selectin) might contribute to
leukocyte binding to injured endothelial cells, constituting a
primary step in plaque formation and subsequent athero-
sclerosis [48], which could ultimately lead to cardiac infarc-
tion or stroke.
Antidiabetic drugs - risk of hypoglycaemia and
cardiovascular events
Although there is some evidence to support a CV protective
role for insulin treatment [84] there are many studies indi-
cating that insulin might be a double-edged sword with re-
gard to CV health because of its associated risk of inducing
hypoglycaemia [6,13,45]. For this reason, studies have begun
to compare various antidiabetic treatments for their relative
likelihood to induce hypoglycaemia in T1D and T2D. The
U.K. Hypoglycaemia Study Group found that mild
hypoglycaemia in T2D patients during early insulin use was
considerably less frequent than in T1D. Also, there was no
difference in the proportion of patients with T2D experien-
cing severe hypoglycaemia after treatment with sulfonyl-
urea compared to insulin [7], while metformin was
associated with a lower risk for hypoglycaemia compared
with conventional therapy with sulfonylurea or insulin.
ORIGIN on the other hand provided evidence that insulin
initiated early in the course of type-2 diabetes does not gen-
erally increased of hypoglycaemia [47]. Generally sulfonyl-
urea are perceived to be associated with increased
cardiovascular risk [85]. Interestingly, it was demonstrated
that a specific sulfonylurea, glibenclamide (also known as
glyburide), was associated with a lower risk of CV compli-
cations compared to treatment using metformin (belonging
to the biguanide class) or rosiglitazone (thiazolidinedione
class) in T2D [86]. However, at the same time, fewer pa-
tients in the rosiglitazone-treated group displayed
hypoglycaemia compared to the glibenclamide-treated pa-
tients [86]. Overall these findings regarding increased risk
of hypoglycaemia with use of insulin and sulfonylureas
were verified in a recent systematic review of the literature,
which compared these two conventional treatments with
metformin, pioglitazone, alpha-glucosidase inhibitors,
incretin mimetics (DPP4-Inhibitors, GLP1-analogues), and
bile acid sequestrants during treatment of T2D [87]. Par-
ticularly, there has been recent discussion regarding
incretin-based therapies and their potential benefit in re-
gard to the risk for hypoglycaemia and CVD; however,
more research is required [88-90].Discussion
Principal findings
Recent results from comprehensive clinical trials, which
demonstrated increased rates of hypoglycaemia with inten-
sive diabetes therapy, have added to the uncertainty sur-
rounding the role of hypoglycaemia in CVD, but at the
same time have encouraged scientists to more thoroughly
investigate the potential mechanistic impact of
hypoglycaemia in CV risk. So far, studies indicate that
hypoglycaemia increases CV dysfunction through many risk
factors (Table 3), including increased thrombotic tendency,
abnormal cardiac repolarization, inflammation, and develop-
ment of atherosclerosis. These hypoglycaemia-associated
risk factors contribute to events such as arrhythmia, silent
myocardial ischemia/angina, myocardial infarction, and
stroke during diabetes.
Strengths and limitations
Major strengths of recent large clinical trials investigating
the role of hypoglycaemia in CVD include access to large
patient cohorts in multi-centre studies, as well as the ability
to do long-term follow-ups and retrospective studies. How-
ever, one major limitation of these trials is the inability to
assign the cause of death with certainty to hypoglycaemia.
In many cases hypoglycaemia is asymptomatic, which
means that it can be challenging to assess its contribution
to CV complications during diabetes. This ambiguity has
been a barrier to assessing and analysing patient data dur-
ing these investigations.
Related to mechanistic studies, a major strength is that
hypoglycaemic responses can be induced in healthy sub-
jects, which are a very useful tool for examining the di-
verse effects of acute hypoglycaemia. Moreover, these
results can then be easily compared with diabetic individ-
uals. The major limitation of the mechanistic research de-
scribed here is that, for the most part, it consists of
observational studies. Thus, factors that are altered during
hypoglycaemia (i.e. cytokines, thrombotic factors, etc.)
have not been concretely demonstrated to contribute dir-
ectly to hypoglycaemia-mediated CV dysfunction in dia-
betes. More study will be required to ascertain which
factors are the most important in this regard, and whether
there is truly a combinatorial effect that drives CVD.
Possible causal explanations for variation within existing
literature
From the studies analysed here, the most obvious discrep-
ancies occurred within the results of the major clinical tri-
als. For example, the significant increase in death
associated with intensive therapy of patients with existing
CVD and/or CV risk in the ACCORD trial was not ob-
served in the other studies [8]. Moreover, the ACCORD in-
vestigators could not ascertain the underlying cause for
this difference in mortality [43,44]. In fact, only the
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hypoglycaemia with increased risk for macrovascular
events and CV-related death [6]. Thus, it remains plaus-
ible that hypoglycaemia could have influenced the results
observed in the ACCORD trial since it is difficult to reli-
ably assign the potential contribution of hypoglycaemia to
these deaths. Additionally, although slight CV benefit
was observed in some of these trials, overall it was not
significant, and it is possible that the true advantages of
intensive therapy will not be noted until much later as
suggested by the UKPDS and DCCT/EDIC trials [40,42].
Finally, it is interesting that the observed rates of hypo-
glycaemia were variable; yet, it seems undeniable that col-
lectively the data reveal significantly increased episodes of
severe hypoglycaemia with intensive treatment. Thus,
even though there are some discrepancies between these
trials, the overall findings support the necessity for a more
thorough understanding of the effects of this common
complication in diabetes.
Unanswered questions and implications for future work
There are several questions and future implications that arise
from this work. For example, hypoglycaemia is known to be
a regular event for insulin-requiring diabetic patients; how-
ever, if hypoglycaemia is strongly linked to CV risk, then it
remains unclear why many patients do not show CV prob-
lems after repeated exposure to hypoglycaemic episodes. The
determining factors for this might include genetic traits,
which could be identified through future investigation. More-
over, there has been some debate over whether
hypoglycaemia is simply a marker of vulnerability for CVD
or a cause for it [6], which will only be resolved through con-
tinued research regarding the potential direct mechanistic
roles of hypoglycaemia in CVD. Future studies using tech-
niques such as CGM will hopefully continue to shed light on
the potential contributions of hypoglycaemia to CVD. Add-
itionally, the fact that delayed CV benefit was reported fol-
lowing intensive diabetes therapy is an intriguing result that
warrants more study [40,42]. Also, because hypoglycaemia
has potentially life-threatening effects for diabetes patients,
the continued characterization of antidiabetic treatments that
have reduced risk for causing hypoglycaemia is essential for
the management of diabetes. These drugs could then be uti-
lized in future trials to establish whether hypoglycaemia is
truly a barrier to benefit during intensive therapy.
Conclusions
Overall, we conclude that while recent studies have made
significant progress in our understanding of the role of
hypoglycaemia in CVD, further research will be necessary
to fully ascertain the impact of hypoglycaemia on the CV
system in T1D and T2D. For the time being therefore,
the consideration of hypoglycaemia risk appears to be
warranted for the selection of antidiabetic pharmacotherapy.Abbreviations
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